CORDIS
EU research results

CORDIS

English EN

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development

Objective

The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Expressions of Interest (EoI) prior to this application and to which interested parties could respond. In total, 115 EoIs were received and ranked by the TBVI Steering Committee using proposed H2020 evaluation criteria. This led to the prioritisation of 52 R&D approaches included in this proposal.
TBVAC2020 aims to innovate and diversify the current TB vaccine and biomarker pipeline while at the same time applying portfolio management using gating and priority setting criteria to select as early as possible the most promising TB vaccine candidates, and accelerate their development. TBVAC2020 proposes to achieve this by combining creative “bottom-up” approaches for vaccine discovery (WP1), new preclinical models addressing clinical challenges (WP2) and identification and characterisation of correlates of protection (WP5) with a directive “top-down” portfolio management approach aiming to select the most promising TB vaccine candidates by their comparative evaluation using objective gating and priority setting criteria (WP6) and by supporting direct, head-to head or comparative preclinical and early clinical evaluation (WP3, WP4). This approach will both innovate and diversify the existing TB vaccine and biomarker pipeline as well as accelerate development of most promising TB vaccine candidates through early development stages. The proposed approach and involvement of many internationally leading groups in the TB vaccine and biomarker area in TBVAC2020 fully aligns with the Global TB Vaccine Partnerships (GTBVP).
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING TUBERCULOSIS VACCINE INITIATIVE

Address

Runderweg 6
8219 Ph Lelystad

Netherlands

Activity type

Other

EU Contribution

€ 2 473 986,45

Participants (45)

Sort alphabetically

Sort by EU Contribution

Expand all

STATENS SERUM INSTITUT

Denmark

EU Contribution

€ 1 586 952

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 957 480

ASTON UNIVERSITY

United Kingdom

INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE

Belgium

SCIENSANO

Belgium

EU Contribution

€ 111 864

UNIVERSITEIT GENT

Belgium

EU Contribution

€ 23 700

BANGOR UNIVERSITY

United Kingdom

EU Contribution

€ 23 700

UNIVERSITAET ULM

Germany

EU Contribution

€ 604 824

INSTITUT PASTEUR

France

EU Contribution

€ 528 980

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 1 714 513

UNIVERSIDAD DE ZARAGOZA

Spain

EU Contribution

€ 951 792

UNIVERSITE DE GENEVE

Switzerland

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Switzerland

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 220 030,80

YONSEI UNIVERSITY

South Korea

STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

Netherlands

EU Contribution

€ 918 194,88

Department of Health

United Kingdom

EU Contribution

€ 1 416 150,84

UNIVERSITAT ZURICH

Switzerland

INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL

Spain

EU Contribution

€ 415 224

MEDICAL RESEARCH COUNCIL

United Kingdom

UNITED KINGDOM RESEARCH AND INNOVATION

United Kingdom

EU Contribution

€ 396 294,34

STELLENBOSCH UNIVERSITY

South Africa

EU Contribution

€ 284 400

UNIVERSITY OF CAPE TOWN

South Africa

EU Contribution

€ 355 500

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom

EU Contribution

€ 1 194 647,50

AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE DI PALERMO

Italy

EU Contribution

€ 118 500

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 308 100

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 936 937,93

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 218 040

ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

Italy

EU Contribution

€ 218 040

THE UNIVERSITY OF SYDNEY

Australia

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 755 642,50

BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL

Germany

THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS

United Kingdom

EU Contribution

€ 252 686,56

KWAZULU NATAL RESEARCH INSTITUTE FOR TB-HIV (K-RITH) NPC

South Africa

EU Contribution

€ 167 227,20

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

INSTITUT PASTEUR DE LILLE FONDATION

France

EU Contribution

€ 538 464

UNIVERSITE DE LAUSANNE

Switzerland

UNIVERSITAT BASEL

Switzerland

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 206 664

AERAS GLOBAL TB VACCINE FOUNDATION

United States

INTERNATIONAL TUBERCULOSIS RESEARCH CENTER

South Korea

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium

TRANSGENE SA

France

FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT

Germany

EU Contribution

€ 142 200

UNIVERSITY OF STRATHCLYDE

United Kingdom

EU Contribution

€ 159 264

Project information

Grant agreement ID: 643381

Status

Closed project

  • Start date

    1 January 2015

  • End date

    30 June 2019

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 25 056 507,33

  • EU contribution

    € 18 200 000

Coordinated by:

STICHTING TUBERCULOSIS VACCINE INITIATIVE

Netherlands